Diabetes and Heart Disease

 Diabetes significantly increases the risk of

Heart disease Stroke 60 % Chance of dying

by 2–4 fold2 by more than 2–4 fold2 from heart disease3

1. International Diabetes Federation. Diabetes Atlas, Fifth Edition: www.diabetesatlas.org. Accessed 25 June 2012. Estimated
based on mortality data; 2. Adapted from: CDC 2011 National Diabetes Fact Sheet:
http://www.cdc.gov/diabetes/pubs/estimates11.htm#12. Accessed June 2011. 3. NIDDK website. Diabetes, heart Disease,
and Stroke 2017.
 Remogliflozin Etabonate
Chemical Structure Drug Profile

Drug Name: Remogliflozin Etabonate; ester prodrug of

Remogliflozin
• Remogliflozin is a selective inhibitor of
renal SGLT2 (365:1)
• Remogliflozin is a O-glucoside
 Remogliflozin: Indication

 DCGI Approved Indication

• As monotherapy when diet and exercise does not provide
adequate glycemic control

• As add-on to Metformin when together with diet and exercise

does not provide adequate glycemic control
 How it Works:
Remogliflozin increases Urinary glucose excretion via SGLT2 inhibition

Filtered glucose load

> 180 g/day

SGLT2 inhibitors
reduce glucose
re-absorption
in the proximal
SGLT2
SGLT2 tubule, leading to
inhibitor
urinary glucose
excretion* and
osmotic diuresis
SGLT1

*Loss of ~ 80 g of glucose/day (~ 240 cal/day). Gerich JE. Diabet Med. 2010;27:136–142.

 Remogliflozin: Dose

 Dose - 100 mg BD [Twice a Day]

• Can be given with or without Food
 Undesirable side effects
 In a 24-week, randomised, double-blind, double-dummy parallel-group, multi-centre, active-

controlled(Dapagliflozin 10 mg) phase III study,

 Commonly reported adverse reaction ( > 1% incidence) were

• urinary tract infection (4.9%),

• pyrexia (2.7%), headache (2.5%),

• bacteriuria (2.3%),

• constipation (1.7%),

• diarrhoea (1.7%),

• glomerular filtration rate decreased (1.7%),

• ketonuria ( 1.7%), cough (1.5%),

• dyslipidaemia (1 .5%), asthenia (1 .O%),

• viral upper respiratory tract infection ( 1.0%),

• hypoglycaemia (1.0%), and

• orthostatic hypotension (1 .0%).

 For further details please read prescribing
information.
 The matter content in this infographic is solely for
educational purposes only. It does not intend either directly
or indirectly expressly or impliedly to promote, propagate,
advertise or otherwise endorsing any particular product or
brand. The matter content in this infographic does not make
any representation or warranties with respect to the efficacy,
accuracy, usefulness or applicability, or fitness, or
completeness for any particular purpose. The content has
been created by professional medical writers of Intas
pharmaceuticals Ltd. The creators of this infographic hereby
disclaim any and all liability to any party for any direct,
indirect, implied, punitive, special, incidental or other
consequential damages arising directly or indirectly from any
use of this infographics, which is provided as is, and without
warranties.